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Background. Intravesicular Bacillus Calmette-Guérin (BCG) is an effective adjunctive therapy for superficial bladder cancer that
has been shown to delay recurrence and progression of disease. Serious side effects are relatively rare but are difficult to diagnosis
and commonly overlooked. Case Presentation. We report the case of a patient who was found to have mycotic aortic aneurysms
secondary to treatment with BCG after a prolonged course with multiple intervening hospitalizations. Conclusion. Through this
report, we discuss our present understanding of BCG infection following treatment and review the literature regarding this
particular rare manifestation.

1. Background

2. Case Presentation

Bacillus Calmette-Guérin (BCG) is a live attenuated strain
of Mycobacterium bovis commonly used in the management of high-risk non-muscle-invasive bladder cancer [1].
Intravesicular instillation of BCG is believed to provoke an
inflammatory response which when used as an adjunct to
transurethral resection of visible tumor (TURBT) has been
shown to delay both the recurrence rate and the progression
of bladder cancer [2]. Side effects are generally tolerable;
while up to 90% of patients experience cystitis and flulike symptoms for 24 to 48 hours after treatment, multiple
series have shown that serious infections occur in less than
5% of patients overall [3, 4]. These infections are usually
either limited to local structures within the genitourinary
tract or disseminated with fever and organ involvement.
Mycotic aneurysm is a rare and often fatal presentation of this
syndrome [5].
We report here a case of a 72-year-old man who was
diagnosed with a mycotic aneurysm secondary to BCG 8
months after his most recent treatment.

The patient is a 72-year-old man with a history of bladder
cancer diagnosed two years ago now status post two rounds
of intravesicular BCG. His most recent treatment was given
8 months prior to his ultimate diagnosis with BCG-positive
mycotic aneurysms. The indication for treatment was a
recurrence in carcinoma in situ that was picked up on routine
screening. There was no trauma or concern for infection
noted at that time.
He initially presented to an outside emergency room
one month after this second round of BCG with recurrent
fevers and rigors. Urine cultures grew coagulase-negative
Staphylococcus aureus and he was sent home on Macrobid.
He then presented shortly thereafter with increasing lethargy
and was transferred to our facility where he was found to
have an acute kidney injury and pancytopenia of unclear
etiology. His AKI resolved with hydration and work-up for
his pancytopenia was notable for a thyroid nodule that was
biopsied but ultimately found to be benign. Imaging at that
time was notable for a normal abdominal aorta. The patient
declined a bone marrow biopsy. He would then present once
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Figure 1: CT image and 3D reconstruction of aneurysm. (a) Sagittal CT shows saccular infrarenal aneurysm with surrounding inflammation.
(b) 3D reconstruction demonstrates that the relation of the aneurysm to major abdominal arteries calcifications can be readily identified.

more a few months later to an outside facility with worsening
rigors, chills, and fevers. A chest X-ray was concerning for
pneumonia which was treated with cefuroxime.
In the midst of these recurrent hospitalizations, the
patient transferred his care to a urologist with our group.
He was found to have positive urine cytology which was
concerning for a recurrence of his cancer and a CT urogram
was ordered as follow-up (Figure 1). This CT, now 8 months
from his most recent BCG treatment, was notable for two
abdominal aortic aneurysms, both infrarenal. Given that
these aneurysms were not present on his imaging 7 months
earlier, there was a concern for a mycotic process. He was
admitted and underwent open resection of his aneurysms
with inline reconstruction utilizing a rifampin-soaked Gelsoft 16 × 8 mm bifurcated graft. Mycobacterium complex
DNA was isolated from fluid around his aortic wall for
which he was started on rifampin, ethambutol, and isoniazid
(Figure 2). His postoperative course was complicated by
chylothorax and GI bleed requiring transfer to an ICU and
multiple transfusions. He was discharged after a month in
good condition with a follow-up and a plan for 6 months of
therapy with rifampin, ethambutol, and isoniazid.

3. Discussion
Intravesicular BCG is the standard-of-care adjuvant therapy
for the treatment of high-risk non-muscle-invasive bladder
cancer [6]. BCG has been shown to decrease the likelihood
of both recurrence and progression after TURBT, as well as
eradicate residual tumor in greater than 70% of patients with

carcinoma in situ [1, 6, 7]. BCG is generally well tolerated,
with most side effects directly related to the T-cell mediated
inflammatory response that is believed to drive the antitumor
effect of the treatment [6]. As such, BCG therapy can be
thought of as an iatrogenic cystitis, with common symptoms
including urinary frequency, dysuria, and a low grade fever
lasting 24 to 48 hours.
However, around 5% of patients can experience significant morbidity, typically noncaseating granulomatous
inflammation of either local structures within the genitourinary tract or systemic organs, including the lung, liver, and
osteomuscular structures [8]. These reactions were initially
believed to be aseptic, hypersensitivity responses given that
organisms could rarely be cultured or identified with acid-fast
stains of the affected tissue [9]. Improvements in technique
over time and the advent of PCR have led to a revision
of this position, but a 2014 review found that acid-fast
staining, mycobacterial culture, and PCR-based assays were
only positive in 25.3%, 40.9%, and 41.8% of cases, respectively.
The authors emphasized the role of exclusion of other entities
and prompt response to antituberculosis treatment in making
the diagnosis of BCG infection [10].
Furthermore, the time to presentation of these symptoms
can vary dramatically, from days to years after the last
instillation [10]. As such, making the diagnosis can be challenging, especially given that the presenting symptoms are
often difficult to distinguish from more common etiologies
such as pneumonia or urinary tract infection. Moreover, it
appears that BCG infection can be broadly divided into two
syndromes based on time of presentation after instillation.
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Figure 2: Microscopic (hematoxylin and eosin stain) photos of the resected portion of the aorta. (a) Periaortic adipose tissue with abundant
chronic inflammation and fat necrosis. (b) Atherosclerosis and calcifications can be readily identified. (c) Perivascular lymph nodes show
granulomatous inflammation. (d) Occasional giant cells are present in the lymph nodes.

Early BCG infection tends to present within 6 months and
is usually disseminated whereas late BCG infection tends to
involve the genitourinary tract [8].
Our patient’s particular history is complicated by multiple
presentations to medical facilities resulting in diagnoses of
UTI and pneumonia and concern for malignancy in the setting of pancytopenia. While it possible that he in fact suffered
from several infections and has an occult malignancy, BCG
sepsis with recurrent fever, pneumonitis, and bone marrow
involvement resulting in pancytopenia provides a unifying
explanation for the course of his illness [11, 12]. Indeed, the
patient endorsed prolonged fever and shaking chills immediately following his most recent instillation and more or
less continuous symptoms from then on, suggesting ongoing
active mycobacterial infection. It is likely that the patient
suffered an early disseminated infection which continued
progressing until his diagnosis 8 months later, consistent with
the existing literature.
Mycotic aneurysm is rare even among those patients
experiencing systemic complications from BCG therapy,
although it does occur [5]. Overall, we were only able to find
27 cases reported in the literature to date, usually infrarenal
aortic aneurysms like those in our patient [5, 13]. Bladder

cancer patients are more likely to have a history of smoking
and as such are also predisposed to diffuse vascular disease.
This provides a portal of entry for hematogenous seeding
of the vaso vasorum. Mycotic aneurysms tend to present
late after BCG therapy, on average 19 months after the last
instillation, with a prolonged course marked by fever, malaise,
and weight loss. Prognosis is poor, with a 15.8% attributable
mortality rate [10]. This case is unique in that it appears
that the patient suffered an early disseminated infection with
bone marrow and potentially lung involvement that went
unrecognized for several months.

4. Conclusion
BCG infection after therapy is an uncommon but serious side
effect of BCG therapy. Diagnosis is challenging as BCG infection can manifest as multiple syndromes, sometimes years
after treatment. Furthermore, work-up for BCG infection
is often negative. Thus, it is important for clinicians to be
aware of the patient’s history of BCG treatment and consider
BCG infection when confronting an unexplained febrile
illness, especially when granulomas are seen on histology.
Additionally, patients should be aware that the initial cystitis
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and flu-like symptoms following BCG therapy should resolve
after 48 hours and that any persistence of fever, chills, or other
manifestations of sepsis is a cause for concern.
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